IL6 and neoplasm: Consistently, chemokine receptor 5 (CCR5) blockade inhibited IL-6-STAT3 pathway via SOCS3, and anti-CCR5 antibody treatment could inhibit the growth of tumor via upregulated SOCS3 to decrease MDSCs accumulation and immunosuppressive capacity in vivo (51).